Oncothyreon Starts Phase 2 Trial

Xconomy Seattle — 

Oncothyreon (NASDAQ: ONTY), the Seattle-based cancer drug developer, said today it has begun a mid-stage clinical trial for patients with relapsed forms of brain cancer—glioblastoma multiforme. The company is testing whether its treatment, PX-866, is able to help shrink tumors in about 30 patients at seven clinical sites in Canada. The drug is designed to block the activity of the PI3 kinase, one of the hot targets in cancer biology.